Affiliation:
1. Nizhny Novgorod Regional Clinical Oncology Dispensary; Privolzhsky Research Medical University
2. Regional Oncology Clinical Dispensary
3. Nizhny Novgorod Regional Clinical Oncology Dispensary
4. Nizhny Novgorod Regional Clinical Oncology Dispensary; Privolzhsky Research Medical University
Abstract
The search for biological markers to assess metastatic involvement of the lymph nodes in gastric cancer is one of the key steps in determining treatment tactics. The role of Ki-67 as a marker of cell proliferation in gastric cancer remains relevant. The aim of our study is to determine the Ki-67 threshold value for predicting the lymph nodes metastases. A retrospective analysis of 154 patients with gastric cancer showed an independent and statistically significant relationship between the depth of tumor invasion T (p = 0.002), the differentiation grade G (p = 0.010), the value of the Ki-67 index (p < 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p >< 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients>< 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p < < 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients >0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients with Ki-67 > 45 %, we found that the median OS was 32 months [HR 2.2; 95 % CI 1.2–3,9; p = 0.005], while it was not reached in the group with Ki-67 < 45 %.A Ki-67 level of ≥ 45 % is the optimal threshold for determining the likelihood of lymph node metastasis in gastric cancer.
Publisher
Russian Society of Clinical Oncology
Reference14 articles.
1. Sung H., Ferlay J., Siegelet R. L. et. al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71 (3):209–249. https://doi.org/10.3322/caac.21660
2. Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P. A. Gertsena — filial FGBU «NMITS radiologii» Minzdrava Rossii, 2022.131–133. (In Russ.)
3. Ashimov E., Kiselev N., Torgomyan H., et al. Total gastrosplenectomy with distal pancreatectomy for local advanced gastric adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2021;25. https://doi.org/10.14701/ahbps.EP-177
4. de Jong M.H. S., Gisbertz S.S., Henegouwen M.I. B., et al. Prevalence of nodal metastases in the individual lymph node stations for different T-stages in gastric cancer: a systematic review. Updates Surg 2023;75(2):281–290. https:// doi.org/10.1007/s13304-022-01347-w
5. Vos E.L., Nakauchi M., Gönenet M., et al. Risk of Lymph Node Metastasis in T1b Gastric Cancer: An International Comprehensive Analysis from the Global Gastric Group (G3) Alliance. Ann Surg 2023;277(2):e339–e345. https://doi.org/10.1097/SLA.0000000000005332